Idera Pharmaceuticals, Inc. Announces Preliminary Data from Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced preliminary results from a Phase 1 clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. In this trial, healthy subjects in five dosage cohorts received single doses of IMO-3100 from 0.04 to 0.64 mg/kg. IMO-3100 was well tolerated at all dose levels. Subjects who received IMO-3100 showed suppression of tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1ß), interleukin-6 (IL-6), interferon-alpha (IFN-a), and other pro-inflammatory cytokines mediated through TLR7 and TLR9 activation. The Company is planning to present detailed results of the trial at a scientific meeting in the fourth quarter of 2010.